CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Current update on pharmacological strategies of penile cancer.
Current update on pharmacological strategies of penile cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫治疗与靶向治疗的整合已显示出有希望的结果,尤其是在晚期或转移性疾病患者中。尽管这些进展带来了希望,但仍需更多研究来完善治疗策略,使患者从这些新方法中获益。
阴茎癌因其低发病率被认为是一种孤儿恶性肿瘤,这使得研究和临床开发具有挑战性。对其分子生物学和遗传背景的有限了解增加了开发有效疗法的复杂性。涵盖领域:本综述深入探讨了阴茎癌治疗随时间推移的演变——从手术和放疗等传统方式到如今的疫苗。免疫治疗的突破为过继性T细胞疗法(ATCT)、抗血管生成药物、抗体-药物偶联物(ADCs)和双特异性抗体(BsAbs)等治疗带来了希望。
INTRODUCTION: Penile cancer considered an orphan malignancy - due to its low incidence - makes research and clinical development challenging. The limited understanding of molecular biology and genetic landscape adds to the complexity of developing effective therapies. AREAS COVERED: This review takes a closer look at how penile cancer treatment has evolved - from traditional modes like surgery and radiation to now vaccines - over the period of time.
Breakthroughs in immunotherapy offer a ray of hope alongside treatments like adoptive T-cell therapies (ATCT), anti-angiogenic agents, Antibody-Drug Conjugates (ADCs), and Bispecific Antibodies (BsAbs). EXPERT OPINION: The integration of immunotherapy and targeted therapy has demonstrated promising results, particularly in patients with advanced or metastatic disease. While these advancements bring hope, more research is needed to refine treatment strategies to benefit patients from these novel approaches.
MEMBER ACCOUNT
登录成功会直接打开下一页。